Acute Coronary SyndromesACSNCT07268859
Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea
A study testing STANDART CARE and STANDART CARE & FAN THERAPY in people with Acute Coronary Syndromes and Ticagrelor, run by Acibadem University at 2 sites in Turkey (Türkiye).
Trial summary
This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital. It aims to investigate the effect of hand fan therapy on ticagrelor-associated dyspnea in patients receiving ticagrelor. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Acute Coronary Syndromes, Ticagrelor, Dyspnea
- What is being tested?
- STANDART CARE and STANDART CARE & FAN THERAPY
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 110 participants
- Where
- 2 sitesTurkey (Türkiye)
- Study dates
- 15 Mar 2025to 30 Jan 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Between the ages of 18 and 65,
- No severe hearing and vision problems,
- Can speak and understand Turkish,
- Easy to communicate with,
- First-time sufferer of acute coronary syndrome (ACS) for the first time,
- Decided to start ticagrelor therapy,
- Able to adapt to treatment,
- Individuals who volunteered to participate in the research.
Who cannot join
- Having any problem that prevents you from communicating cognitively, emotionally and verbally,
- Obstructive sleep abnormalities,
- Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.),
- With metabolic abnormalities,
- Intubated after the procedure,
- Previously treated with ticagrelor,
Show all 12Show fewer
- Individuals who did not volunteer to participate in the study. Losses to follow up
- Individuals who wish to leave the study voluntarily.
- Saturation value below 95%,
- The one with the arrest,
- Who will not be able to fulfill the requirements of the work,
- Individuals with life-threatening conditions
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)2 sites, 2 recruiting
- Not yet recruiting
İstanbul Üniversitesi-Cerrahapaşa
Istanbul, Avcılar, 34320
- Recruiting
Sağlık Bilimleri Üniversitesi Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim Araştırma Hastanesi
Istanbul, Üsküdar, 34668
About this study
Official title: Effect of Fan Application in Preventing Ticagrelor-associated Dyspnea in Patients With Acute Coronary Syndrome.
This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital. It aims to investigate the effect of hand fan therapy on ticagrelor-associated dyspnea in patients receiving ticagrelor.
Read the detailed description
Patients in the coronary intensive care unit receiving ticagrelor and meeting the inclusion criteria will be included. The study includes two groups: a control group receiving standard care and an experimental group receiving standard care plus hand fan therapy. A total of 110 participants (55 per group) will be recruited. Randomization will be performed using a computer-based randomization program. Due to the nature of the intervention and sample characteristics, participants and the researcher will not be blinded. Data will be analyzed by a statistician not involved in the study, and the findings will be reported.
- Conditions
- Acute Coronary Syndromes, Ticagrelor, Dyspnea
- Being tested
- STANDART CARE, STANDART CARE & FAN THERAPY
- Keywords
- Nursing, Ticagrelor, Hand fan therapy, Dyspnea, Non-pharmacological intervention
- Medical subject headings
- Acute Coronary Syndrome, Dyspnea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
STANDART CAREOther
Routine ward care including semi-Fowler position and breathing exercises. Standard institutional care will be applied. Presence, number, and severity of dyspnea attacks will be recorded during the first 2 hours after ticagrelor administration.
STANDART CARE & FAN THERAPYOther
Also called Fan
In addition to standard care, patients will undergo hand fanning for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The fan will be directed toward the patient's face from a distance of ~15 cm. Dyspnea severity and number of episodes will be recorded during this period.
| Study group | Role | What they receive |
|---|---|---|
| Standard Care (Control Group) | Active comparator | Routine ward care including semi-Fowler position and breathing exercises. Standard institutional care will be applied. Presence, number, and severity of dyspnea attacks will be recorded during the first 2 hours after ticagrelor administration. Receives: Other: STANDART CARE |
| Standard Care + Fan Therapy (Experimental Group) | Experimental | In addition to standard care, patients will undergo hand fanning for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The fan will be directed toward the patient's face from a distance of ~15 cm. Dyspnea severity and number of episodes will be recorded during this period.
Device: Hand Fan Receives: Other: STANDART CARE & FAN THERAPY |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of ticagrelor-associated dyspnea
The proportion of participants who experience dyspnea within 120 minutes following ticagrelor administration will be recorded.
Measured: Time Frame: 0-120 minutes after ticagrelor administration (T1: baseline; T2: 30 min; T3: 60 min; T4: 120 min) Unit of Measure: Percentage of participants (%)
Secondary outcomes (1)
Time to onset of ticagrelor-associated dyspnea
The time interval between ticagrelor administration and the first reported dyspnea episode will be measured in minutes.
Measured: Time Frame: Within 120 minutes after ticagrelor administration (T1-T4) Unit of Measure: Minutes (min)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Dec 2025
- Study start15 Mar 2025
- Primary completion10 Jan 2026 (estimated)
- Study completion30 Jan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Coronary SyndromesStudies of the same condition, open and under way.
- More trials run by Acibadem UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized into two groups: control and experimental. Randomization will be computer-based. Data will be analyzed by a statistician not involved in the study.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 110 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Acibadem University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07268859
- Sponsor's protocol ID
- ATADEK2024-10/449
- Other IDs
- Is an identifier other
- Acronym
- ACS
- Status last verified
- Aug 2025
- First submitted
- 18 Jun 2025
- Last updated
- 8 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Fan Application in Preventing Ticagrelor-associated Dyspnea in Patients With Acute Coronary Syndrome.
- ClinicalTrials.gov ID
- NCT07268859
- Acronym / sponsor ID
- ACS / ATADEK2024-10/449
- Conditions
- Acute Coronary Syndromes, Ticagrelor, Dyspnea
- Keywords
- Nursing, Ticagrelor, Hand fan therapy, Dyspnea, Non-pharmacological intervention
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 110 participants (estimated)
- Lead sponsor
- Acibadem UniversityUniversity, hospital or other
- Study start
- 15 Mar 2025 (actual)
- Primary completion
- 10 Jan 2026 (estimated)
- Study completion
- 30 Jan 2026 (estimated)
- First posted
- 8 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital. It aims to investigate the effect of hand fan therapy on ticagrelor-associated dyspnea in patients receiving ticagrelor.
Detailed description
Patients in the coronary intensive care unit receiving ticagrelor and meeting the inclusion criteria will be included. The study includes two groups: a control group receiving standard care and an experimental group receiving standard care plus hand fan therapy. A total of 110 participants (55 per group) will be recruited. Randomization will be performed using a computer-based randomization program. Due to the nature of the intervention and sample characteristics, participants and the researcher will not be blinded. Data will be analyzed by a statistician not involved in the study, and the findings will be reported.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Participants will be randomized into two groups: control and experimental. Randomization will be computer-based. Data will be analyzed by a statistician not involved in the study.
| Arm | Type | Receives |
|---|---|---|
| Standard Care (Control Group) | Active comparator | Other: STANDART CARERoutine ward care including semi-Fowler position and breathing exercises. Standard institutional care will be applied. Presence, number, and severity of dyspnea attacks will be recorded during the first 2 hours after ticagrelor administration. |
| Standard Care + Fan Therapy (Experimental Group) | Experimental | Other: STANDART CARE & FAN THERAPYIn addition to standard care, patients will undergo hand fanning for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The fan will be directed toward the patient's face from a distance of ~15 cm. Dyspnea severity and number of episodes will be recorded during this period. Device: Hand Fan |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Between the ages of 18 and 65,
- No severe hearing and vision problems,
- Can speak and understand Turkish,
- Easy to communicate with,
- First-time sufferer of acute coronary syndrome (ACS) for the first time,
Key exclusion criteria (12 listed)
- Having any problem that prevents you from communicating cognitively, emotionally and verbally,
- Obstructive sleep abnormalities,
- Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.),
- With metabolic abnormalities,
- Intubated after the procedure,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| STANDART CARERoutine ward care including semi-Fowler position and breathing exercises. Standard institutional care will be applied. Presence, number, and severity of dyspnea attacks will be recorded during the first 2 hours after ticagrelor administration. | Other | Standard Care (Control Group) |
| STANDART CARE & FAN THERAPYAlso: FanIn addition to standard care, patients will undergo hand fanning for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The fan will be directed toward the patient's face from a distance of ~15 cm. Dyspnea severity and number of episodes will be recorded during this period. | Other | Standard Care + Fan Therapy (Experimental Group) |
Primary outcome
Incidence of ticagrelor-associated dyspnea
Time frame: Time Frame: 0-120 minutes after ticagrelor administration (T1: baseline; T2: 30 min; T3: 60 min; T4: 120 min) Unit of Measure: Percentage of participants (%)
The proportion of participants who experience dyspnea within 120 minutes following ticagrelor administration will be recorded.
1 secondary outcome
Time to onset of ticagrelor-associated dyspnea
Time frame: Time Frame: Within 120 minutes after ticagrelor administration (T1-T4) Unit of Measure: Minutes (min)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Acute Coronary Syndromes
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Recruiting
AI-Assisted Interpretation of Cardiac CT in the Emergency Department
Chest Pain, Acute Coronary Syndrome
Enrolling by invitation
Optical Coherence Tomography in Acute Vessel Evaluation
Ischemic Heart Disease, Ischemic Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing STANDART CARE and STANDART CARE & FAN THERAPY in people with Acute Coronary Syndromes and Ticagrelor, run by Acibadem University at 2 sites in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Emine Tuğba YORULMAZ, research assistant (+905556177281, tugbayoorlmz@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of ticagrelor-associated dyspnea (time frame: Time Frame: 0-120 minutes after ticagrelor administration (T1: baseline; T2: 30 min; T3: 60 min; T4: 120 min) Unit of Measure: Percentage of participants (%)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2025.